SCHEMBL7535800

SCHEMBL7535800

CC(C)(C)OC(=O)N1CCN(c2ccccc2O)C(=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 2/20 0.49
SMARCA4 P51532 2/20 0.49
PBRM1 Q86U86 2/20 0.49
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK1 P28482 1/20 0.46
ESR2 Q92731 1/20 0.44
NR1H2 P55055 2/20 0.43
PDE4B Q07343 1/20 0.42
PDE7A Q13946 1/20 0.42
TERT O14746 1/20 0.42
GPR119 Q8TDV5 1/20 0.41
P2RX7 Q99572 2/20 0.41
DTYMK P23919 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
BCHE P06276 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653185 0.87 P2RX7 (0.55) SMARCA2SMARCA4PBRM1MAPK1ESR2
SCHEMBL1663013 0.86 P2RX7 (0.56) MAPK1P2RX7
SCHEMBL30734152 0.86 MEN1 (0.51) SMN1; SMN2MAPK1NR1H2P2RX7MAPT
SCHEMBL1583488 0.86 MEN1 (0.51) SMN1; SMN2MAPK1NR1H2P2RX7MAPT
SCHEMBL2604325 0.84 MAPK1 (0.44) SMARCA2SMARCA4PBRM1MAPK1ESR2
SCHEMBL2604326 0.84 PDE4B (0.44) MAPK1ESR2NR1H2PDE4BPDE7A
SCHEMBL1583986 0.83 GPR119 (0.44) SMARCA2SMARCA4PBRM1MAPK1NR1H2
SCHEMBL3068738 0.83 GPR119 (0.53) MAPK1ESR2NR1H2GPR119DTYMK
SCHEMBL2382922 0.81 GAA (0.69) SMARCA2SMARCA4PBRM1GAASMN1; SMN2
SCHEMBL30613376 0.81 GAA (0.69) SMARCA2SMARCA4PBRM1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052380-A1 Inhibitors of prenyl-protein transferase DINSMORE CHRISTOPHER J (US) 2002-05-02 US disclosed
US-20020010184-A1 Inhibitors of prenyl-protein transferase DINSMORE CHRISTOPHER J (US) 2002-01-24 US disclosed
WO-2001060368-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-08-23 WO disclosed
WO-2001060815-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-08-23 WO disclosed
US-6103723-A INHIBIT FARNESYL-PROTEIN TRANSFERASE (FTASE) AND THE FARNESYLATION OF THE ONCOGENE PROTEIN RAS; ANTICARCINOGENIC AGENTS; CONFORMATIONALLY CONSTRAINED COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY; INHIBITION OF POST-TRANSLATIONAL MERCK & CO., INC. (US) 2000-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010184-A1 Inhibitors of prenyl-protein transferase FNTA, FNTB, ZMPSTE24 SMARCA2 3685/4885SMARCA4 3047/4885PBRM1 1643/4885
US-20020052380-A1 Inhibitors of prenyl-protein transferase FNTA, FNTB, GGPS1 SMARCA2 3748/4885SMARCA4 3220/4885PBRM1 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.